These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28412587)

  • 1. Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years.
    Engelhardt EG; van den Broek AJ; Linn SC; Wishart GC; Rutgers EJT; van de Velde AO; Smit VTHBM; Voogd AC; Siesling S; Brinkhuis M; Seynaeve C; Westenend PJ; Stiggelbout AM; Tollenaar RAEM; van Leeuwen FE; van 't Veer LJ; Ravdin PM; Pharaoh PDP; Schmidt MK
    Eur J Cancer; 2017 Jun; 78():37-44. PubMed ID: 28412587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study.
    Mook S; Schmidt MK; Rutgers EJ; van de Velde AO; Visser O; Rutgers SM; Armstrong N; van't Veer LJ; Ravdin PM
    Lancet Oncol; 2009 Nov; 10(11):1070-6. PubMed ID: 19801202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the online prediction tool PREDICT v. 2.0 in the Dutch breast cancer population.
    van Maaren MC; van Steenbeek CD; Pharoah PDP; Witteveen A; Sonke GS; Strobbe LJA; Poortmans PMP; Siesling S
    Eur J Cancer; 2017 Nov; 86():364-372. PubMed ID: 29100191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validity of Adjuvant! Online program in older patients with breast cancer: a population-based study.
    de Glas NA; van de Water W; Engelhardt EG; Bastiaannet E; de Craen AJ; Kroep JR; Putter H; Stiggelbout AM; Weijl NI; van de Velde CJ; Portielje JE; Liefers GJ
    Lancet Oncol; 2014 Jun; 15(7):722-9. PubMed ID: 24836274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients.
    Lambertini M; Pinto AC; Ameye L; Jongen L; Del Mastro L; Puglisi F; Poggio F; Bonotto M; Floris G; Van Asten K; Wildiers H; Neven P; de Azambuja E; Paesmans M; Azim HA
    Br J Cancer; 2016 Dec; 115(12):1471-1478. PubMed ID: 27802449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validity of the online PREDICT tool in older patients with breast cancer: a population-based study.
    de Glas NA; Bastiaannet E; Engels CC; de Craen AJ; Putter H; van de Velde CJ; Hurria A; Liefers GJ; Portielje JE
    Br J Cancer; 2016 Feb; 114(4):395-400. PubMed ID: 26783995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
    Bueno-de-Mesquita JM; van Harten WH; Retel VP; van 't Veer LJ; van Dam FS; Karsenberg K; Douma KF; van Tinteren H; Peterse JL; Wesseling J; Wu TS; Atsma D; Rutgers EJ; Brink G; Floore AN; Glas AM; Roumen RM; Bellot FE; van Krimpen C; Rodenhuis S; van de Vijver MJ; Linn SC
    Lancet Oncol; 2007 Dec; 8(12):1079-1087. PubMed ID: 18042430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Nottingham Prognostic Index and Adjuvant Online prognostic tools in young women with breast cancer: review of a single-institution experience.
    Hearne BJ; Teare MD; Butt M; Donaldson L
    BMJ Open; 2015 Jan; 5(1):e005576. PubMed ID: 25628047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
    Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the PREDICT Prognostication Tool in US Patients With Breast Cancer.
    Stabellini N; Cao L; Towe CW; Miller ME; Sousa-Santos AH; Amin AL; Montero AJ
    J Natl Compr Canc Netw; 2023 Oct; 21(10):1011-1019.e6. PubMed ID: 37856198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Underestimated survival predictions of the prognostic tools Adjuvant! Online and PREDICT in BRCA1-associated breast cancer patients.
    Plakhins G; Irmejs A; Gardovskis A; Subatniece S; Liepniece-Karele I; Purkalne G; Teibe U; Trofimovics G; Miklasevics E; Gardovskis J
    Fam Cancer; 2013 Dec; 12(4):683-9. PubMed ID: 23640109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society.
    Ahn SH; Son BH; Kim SW; Kim SI; Jeong J; Ko SS; Han W;
    J Clin Oncol; 2007 Jun; 25(17):2360-8. PubMed ID: 17515570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in Denmark.
    Christiansen P; Bjerre K; Ejlertsen B; Jensen MB; Rasmussen BB; Lænkholm AV; Kroman N; Ewertz M; Offersen B; Toftdahl DB; Møller S; Mouridsen HT;
    J Natl Cancer Inst; 2011 Sep; 103(18):1363-72. PubMed ID: 21881042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model.
    Ozanne EM; Braithwaite D; Sepucha K; Moore D; Esserman L; Belkora J
    J Clin Oncol; 2009 Jan; 27(2):214-9. PubMed ID: 19047286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer.
    Kennedy CR; Gao F; Margenthaler JA
    J Surg Res; 2010 Sep; 163(1):52-7. PubMed ID: 20599225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.
    Johansson P; Fohlin H; Arnesson LG; Dufmats M; Nordenskjöld K; Nordenskjöld B; Stål O;
    Acta Oncol; 2009; 48(4):504-13. PubMed ID: 19235568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic models in male breast cancer.
    van der Pol CC; Lacle MM; Witkamp AJ; Kornegoor R; Miao H; Bouchardy C; Borel Rinkes I; van der Wall E; Verkooijen HM; van Diest PJ
    Breast Cancer Res Treat; 2016 Nov; 160(2):339-346. PubMed ID: 27671991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy validation of adjuvant! online in Taiwanese breast cancer patients--a 10-year analysis.
    Yao-Lung K; Dar-Ren C; Tsai-Wang C
    BMC Med Inform Decis Mak; 2012 Sep; 12():108. PubMed ID: 22985190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple negative breast cancer: adjuvant chemotherapy effect on survival.
    Steponaviciene L; Lachej-Mikeroviene N; Smailyte G; Aleknavicius E; Meskauskas R; Didziapetriene J
    Adv Med Sci; 2011; 56(2):285-90. PubMed ID: 22112429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.